Dennis Hadjiyiannakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dennis Hadjiyiannakis has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Leonie Eastlake
Royal Cornwall Hospital NHS Trust, Truro, UK
2 shared publications - Aashish Vyas
Department of Respiratory Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK
1 shared publication - Anthony J. Chalmers
School of Cancer Sciences, University of Glasgow , Glasgow
1 shared publication - David Cameron
National Institute of Health and Care Research Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK
1 shared publication - Dimitri Alex Dimitroyannis
Value Institute for Health and Care, Dell Medical School, UT Austin, Austin, Texas; Edward Hines Jr VA Hospital, Hines, Illinois
1 shared publication - Emma Hudson
Velindre Cancer Centre, Cardiff, UK
1 shared publication
Latest Publications
- 2 July 2025
- Published by Elsevier in Clinical Oncology
- Vol. 45, 103899
Real World Multi-centre UK Review of Nivolumab Monotherapy in Metastatic Endometrial Cancer With Mismatch Repair Deficiency During COVID-19
- 2 July 2025
- Published by Elsevier in Clinical Oncology
- Vol. 45, 103899
Real World Multi-centre UK Review of Nivolumab Monotherapy in Metastatic Endometrial Cancer With Mismatch Repair Deficiency During COVID-19
- Open Access
Low-Dose Radiotherapy for Severe COVID-19 Lung Disease—Have Meta-Analyses Accounted for Dose and Timing of Radiotherapy?
Low-dose radiotherapy had historically been used to treat both bacterial and viral pneumonias. In the present day, this is not in use due to the development of antibiotics and other supportive measures as well as a concern regarding late radiation toxicities. COVID-19 presented us with a novel respiratory illness without a strong evidence-based best practice; it was thought, therefore, that there may be a role for low-dose radiotherapy in the absence or failure of a standard treatment. The rationale for this was based around the ability of low-dose radiation to reduce an inflammatory state. We treated two individuals suffering from severe COVID-19 with low-dose whole lung radiotherapy, in the setting of a phase I trial. Both patients improved clinically, biochemically, and radiologically within a matter of days. We discuss why the meta-analyses may not have shown this advantage.
Open AccessLow-Dose Radiotherapy for Severe COVID-19 Lung Disease—Have Meta-Analyses Accounted for Dose and Timing of Radiotherapy?
Low-dose radiotherapy had historically been used to treat both bacterial and viral pneumonias. In the present day, this is not in use due to the development of antibiotics and other supportive measures as well as a concern regarding late radiation toxicities. COVID-19 presented us with a novel respiratory illness without a strong evidence-based best practice; it was thought, therefore, that there may be a role for low-dose radiotherapy in the absence or failure of a standard treatment. The rationale for this was based around the ability of low-dose radiation to reduce an inflammatory state. We treated two individuals suffering from severe COVID-19 with low-dose whole lung radiotherapy, in the setting of a phase I trial. Both patients improved clinically, biochemically, and radiologically within a matter of days. We discuss why the meta-analyses may not have shown this advantage.